News and Trends 12 Oct 2022
Agreement signed to advance therapy for autoimmune disease
HanAll Biopharma’s licensed partner, Harbour BioMed, has signed an exclusive sublicense agreement with CSPC NBP Pharmaceutical Co., Ltd for an advanced inhibitor. The agreement is for HanAll’s neonatal Fc receptor…